Septerna
SEPN | NASDAQ
$41.67
-$0.93 (-2.18%)
At close: Nov 16, 2026, 4:00 PM ET
$41.67
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Septerna Company Profile
Company profile explainedCompany Profile
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Jeffrey T. Finer | Co-Founder, Chief Executive Officer & Director |
| Elizabeth Bhatt | President & Chief Operating Officer |
| Gilbert Labrucherie | Chief Financial Officer |
| Mark A. Wilson | Chief Legal Officer |
| Samira Shaikhly | Chief People Officer |
| Arthur Christopoulos BPHARM | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| George Xu | Senior Director of Corporate Development & Portfolio Strategy |
| Patrick Sexton | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Richard Hansen | Vice President of Technology |
| Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 03, 2026 | 3 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13D/A | [Amend] Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 4 | Filing |
Septerna
| Country | United States |
| IPO Date | Oct 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Jeffrey T. Finer |
Contact Details
250 East Grand Avenue South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | SEPN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001984086 |
| CUSIP Number | 81734D104 |
| ISIN Number | US81734D1046 |
| SIC Code | 2834 |
Recent News
- 5 days ago / seekingalpha.comSepterna: The SEP-479 Readout Could Unlock Further Upside
- 7 days ago / zacks.comSepterna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates
- 13 days ago / globenewswire.comSepterna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
- 14 days ago / globenewswire.comSepterna to Participate in Upcoming Investor Conferences
- 3 months ago / globenewswire.comSepterna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
- 3 months ago / zacks.comSepterna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
- 5 months ago / fool.comIs Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
- 6 months ago / zacks.comSepterna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
- 6 months ago / globenewswire.comSepterna Highlights Business Progress and Reports First Quarter 2026 Financial Results
- 7 months ago / globenewswire.comSepterna to Present at Bank of America Securities Health Care Conference
Add to Watchlist
Select watchlists to add or remove SEPN